Next-generation sequencing (454, Solexa/Illumina)
Secuenciación de nueva generación (454, Solexa/Illumina)
- Date
- 2005-2006 · confidence high
- Place
- 454 Life Sciences, Branford, Connecticut, United States; Solexa, Cambridge, United Kingdom
- Credited to
- Jonathan Rothberg (454); Shankar Balasubramanian and David Klenerman (Solexa, acquired by Illumina in 2007)
- People
- 👤 David Klenerman1959–👤 Jonathan M. Rothberg1963–👤 Shankar Balasubramanian1966–
- Field
- Life & health
What it is
Massively parallel sequencing of millions of fragments at once, which cut the cost of a genome from 100 million dollars to under 1,000. It made genomics routine.
What it led to
- Sequencing of tumours, microbiomes and pathogens (SARS-CoV-2 surveillance)
- Non-invasive prenatal diagnosis and newborn genomes
- Palaeogenomics and big-data evolutionary biology
Built on
- Sanger DNA sequencing1977
- Polymerase chain reaction (PCR)1983
- Thermostable Taq polymerase and automated PCR1976-1988
- Human Genome Project1990-2003
- Sanger sequencing
- CCD/CMOS sensor
- Human Genome Project
Made possible
- Neanderthal genome and Denisovans2010
- Human microbiome2007-2012
- Nanopore DNA sequencing (Oxford Nanopore MinION)1996-2014
- AlphaFold protein structure prediction2020
- mRNA vaccine (COVID-19)2020
- Genomic detection of Beta and Omicron variants2020-2021
- liquid biopsy
- non-invasive prenatal test
- genomic surveillance of epidemics
- nanopore sequencing